First Generic Versions of Ondansetron Tablets, Orally Disintegrating Tablets and Oral Solution, USFDA Approved
Zofran (Ondansetron) Tablets, Orally Disintegrating Tablets and Oral Solution are indicated for the prevention of nausea and vomiting associated with surgery, radiotherapy and cancer chemotherapy.
The USFDA has just recently approved the first generic versions of Zofran (Ondansetron) Tablets, Orally Disintegrating Tablets and Oral Solution, which proved to be an important step in the USFDA’s effort in increasing the availability of lower-cost generic medications.
Ondansetron Hydrochloride Tablets (4 mg, 8 mg, 16 mg and 24 mg) are manufactured by Dr. Reddy Laboratories, Ltd. (NYSE: RDY) Bridgewater, NJ 08807. - Ondansetron Orally Disintegrating Tablets (4 mg, 8 mg, 16 mg and 24 mg) are manufactured by Kali Laboratories, Inc. (company acquired by Par Pharmaceutical, NYSE: PRX), Somerset, NJ 08873
- Ondansetron Hydrochloride Oral Solution (4mg (base)/5 mL) is manufactured by Roxane Laboratories, Inc.(4273797), Columbus, OH 43228
In 2005, Ondansetron was the 20th highest-selling brand-name drug in the United States in 2005, with sales totaling $839,256,543 as reported in the online magazine Drug Topics.
Zofran is a product of GlaxoSmithKline (NYSE: GSK).
Source: FDA News
Comment Preview